Braveheart Bio prices IPO at $18 per share
Braveheart Bio priced its IPO at $18 per share, raising $382.5 million before underwriting fees. Shares are set to start trading on Nasdaq on Aug. 6, 2026 under BRVE, with an expected Aug. 7 close. Proceeds will fund development of BHB-1893, an oral cardiac myosin inhibitor for HCM, including Phase III. The asset was licensed from Jiangsu Hengrui Pharmaceuticals.
How this was made
The 30-second read
Why it matters
The disclosed IPO terms (price, proceeds, listing date) and the specific clinical development plan provide a concrete near-term catalyst for trading the new listing, while longer-term valuation hinges on BHB-1893 clinical outcomes.
Market read
Traders can position around the first trading session and assess dilution and funding runway based on the IPO proceeds and stated clinical use.
What to watch
The article does not disclose the total amount sought in the filing, and it is unclear how much dilution the 30-day underwriter option adds to the effective float and valuation.
Background
Braveheart Bio is launching on Nasdaq via an IPO, with proceeds earmarked for advancing BHB-1893 in obstructive and non-obstructive hypertrophic cardiomyopathy.
Ticker impact
Braveheart Bio priced its IPO at $18 and said proceeds will fund development of BHB-1893, including a Phase III trial.
Likely supportive for first-day liquidity and sentiment, but follow-through depends on clinical/regulatory milestones for BHB-1893.
The article discloses a fresh capital raise (IPO price, size of proceeds) and a specific clinical development plan, which are actionable for positioning around listing and early trading.
Market effects
Adds another HCM-focused biotech financing story, reinforcing investor appetite for cardiac myosin inhibitor programs and Hengrui-licensed assets.
Primarily US-focused listing and biotech capital markets flow.
Limited, unless the Hengrui licensing model or HCM drug class draws broader cross-border investor attention.
Counterpoint
IPO proceeds and a Phase III intent do not guarantee trial success; early trading can fade if investors discount preclinical-to-Phase III execution risk.
Key entities
- companyBraveheart Bio
San Francisco-based firm pricing an IPO at $18 and planning to use proceeds to advance BHB-1893 toward Phase III.
- drug_programBHB-1893
Oral cardiac myosin inhibitor for hypertrophic cardiomyopathy, including plans for Phase III in obstructive HCM.
- partnerJiangsu Hengrui Pharmaceuticals
Licensing partner for the asset, with the agreement described as worth up to $1 billion.